...
首页> 外文期刊>Journal of Medicinal Chemistry >Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978)
【24h】

Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978)

机译:再次探讨抗血吸虫芳基乙内酰脲的SAR(Ro 13-3978)

获取原文
获取原文并翻译 | 示例

摘要

The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD(7.4), aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.
机译:芳基乙内酰脲1(Ro 13-3978)在1980年代初期被确认为有前途的抗血吸虫病铅化合物。然而,这一系列芳基乙内酰脲在宿主体内产生抗雄激素副作用,鉴于其与抗雄激素药物尼鲁米特的结构相似,这并非意料之外的结果。基于此化合物系列的已知SAR,我们现在描述1的许多类似物,这些类似物旨在通过引入已知会减少配体与雄激素受体相互作用的亚结构和官能团来最大程度地指导结构多样性。这些类似物具有计算出的极表面积(PSA),测得的LogD(7.4),水动力学溶解度以及估计的血浆蛋白结合值,其范围预测了良好的ADME谱。 SAR的主要见解是高抗血吸虫活性需要1个乙内酰脲核心。我们鉴定了几种抗血吸虫药功效较高的化合物,其抗雄激素性低于1。这些数据为正在进行的抗血吸虫药乙内酰脲优化提供了方向。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号